PMID- 11557268
OWN - NLM
STAT- MEDLINE
DCOM- 20011101
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 427
IP  - 2
DP  - 2001 Sep 14
TI  - Tranilast inhibits interleukin-1beta-induced monocyte chemoattractant protein-1 
      expression in rat mesangial cells.
PG  - 151-8
AB  - Monocyte chemoattractant protein-1 (MCP-1), a member of the CC subfamily of 
      chemokines, plays a crucial role in the progression of glomerulonephritis by 
      recruitment of monocytes. Tranilast, a clinically used anti-allergic drug, has 
      been demonstrated to have various anti-inflammatory and anti-proliferative 
      effects, and recently has been reported to prevent restenosis after percutaneous 
      transluminal coronary angioplasty. In this study, we investigated whether 
      tranilast inhibits MCP-1 secretion in mesangial cells. Tranilast inhibited 
      interleukin-1beta-induced MCP-1 secretion and mRNA expression in a 
      concentration-dependent manner. Luciferase assay showed that tranilast suppressed 
      interleukin-1beta-induced nuclear factor-kappaB (NF-kappaB)-dependent 
      transcription. Interleukin-1beta-induced Jun N-terminal kinase (JNK) activation 
      was also suppressed selectively by tranilast. These results indicate that 
      tranilast inhibits interleukin-1beta-induced MCP-1 production, at least in part, 
      by inhibiting NF-kappaB activity and that suppression of JNK activation might be 
      involved in the inhibition of MCP-1 production. Tranilast may serve as a new 
      therapeutic agent for glomerulonephritis through anti-chemokine property.
FAU - Chikaraishi, A
AU  - Chikaraishi A
AD  - Department of Internal Medicine, Keio University School of Medicine, 35 
      Shinanomachi, Shinjuku, 1608582 Tokyo, Japan.
FAU - Hirahashi, J
AU  - Hirahashi J
FAU - Takase, O
AU  - Takase O
FAU - Marumo, T
AU  - Marumo T
FAU - Hishikawa, K
AU  - Hishikawa K
FAU - Hayashi, M
AU  - Hayashi M
FAU - Saruta, T
AU  - Saruta T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukin-1)
RN  - 0 (NF-kappa B)
RN  - 0 (RNA, Messenger)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (ortho-Aminobenzoates)
RN  - EC 1.13.12.- (Luciferases)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - HVF50SMY6E (tranilast)
SB  - IM
MH  - Animals
MH  - Cells, Cultured
MH  - Chemokine CCL2/*genetics
MH  - Gene Expression Regulation/drug effects
MH  - Glomerular Mesangium/cytology/*drug effects/metabolism
MH  - Interleukin-1/*pharmacology
MH  - Luciferases/genetics/metabolism
MH  - Mitogen-Activated Protein Kinases/drug effects/metabolism
MH  - NF-kappa B/genetics/metabolism
MH  - RNA, Messenger/drug effects/genetics/metabolism
MH  - Rats
MH  - Recombinant Fusion Proteins/genetics/metabolism
MH  - ortho-Aminobenzoates/*pharmacology
EDAT- 2001/09/15 10:00
MHDA- 2001/11/03 10:01
CRDT- 2001/09/15 10:00
PHST- 2001/09/15 10:00 [pubmed]
PHST- 2001/11/03 10:01 [medline]
PHST- 2001/09/15 10:00 [entrez]
AID - S0014-2999(01)01215-8 [pii]
AID - 10.1016/s0014-2999(01)01215-8 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2001 Sep 14;427(2):151-8. doi: 10.1016/s0014-2999(01)01215-8.